Profile – Dr Loukia Katsouri, University College London
Senior Research Fellow at the UCL Gatsby Foundation and Wellcome Trust working on the Basic mechanisms of Neurodegeneration.
All posts by Dementia Researcher
Podcast – AAIC 2024 Preview
In this podcast we hear from Dr Claire Sexton, Alzheimer’s Association’s Senior Director, Scientific Programs and Outreach to learn what they have planned for us at the AAIC
Profile – Professor Arlene Astell, Northumbria University
Professor of CyberPsychology working with people living with dementia and carers to innovate and test new approaches and treatment and care interventions.
Profile – Dr Jessica Z. K. Caldwell, Cleveland Clinic
Director, Women’s Alzheimer’s Movement Prevention exploring Sex differences in Alzheimer’s disease biomarkers and reducing Alzheimer’s risk in women
How to prepare for the new NIH Simplified Review Framework
NIH blog flagging significant future adjustments on the horizon for NIH peer review for applications – ensure you’re on top of what’s to come
NCRM Annual Lecture – AI in Social Research
Noortje Marres, Carrie Friese and Rachel Coldicutt deliver the annual NCRM lecture exploring the use of AI in Social Research and challenges
Profile – Dr Ece Bayram, University of Colorado Denver
Assistant Professor and ISTAART Lewy body Dementias PIA researching sex, gender, ethnic and racial differences in neurodegenerative Parkinsonian diseases.
Using research activity data to plan and place your trial
Unlock deeper insight and intelligence from data by comparing external data sets against real-time research activity data – advise film from the NIHR.
Profile – Lluís Camprubí Ferrer, Lund University
PhD Student exploring Neuroinflammation in Alzheimer’s at Lund University, in Sweden – avid absorber of knowledge and asker of questions.
UCL Movement Disorders Symposium
Catch-up on this Seminar and hear from international experts on recent discoveries and promising pathways to understand, monitor and treat movement disorders.
Donanemab approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s
With FDA Approval for Donanemab confirmed, it now has a new name…. welcome to Kisunla™ for the Treatment of Early Symptomatic Alzheimer’s Disease.
Blog – Ultimate guide to making the most of the AAIC
Discover Dr Helena Gellersen’s comprehensive guide and insights on maximising your conference attendance and AAIC experiences. Read the blog now!